

From: (b) (6)
Sent: Sat, 7 Mar 2020 09:11:12 -0500
To: Auchincloss, Hugh (NIH/NIAID) [E]
Subject: Fwd: JID 2006, 193:1244-1249
Attachments: SARS & gd T cells.pdf, ATT00001.htm

Pls respond if required

Sent from my iPhone

Begin forwarded message:

From: MIROSLAV MALKOVSKY (b) (6)
Date: March 6, 2020 at 4:46:28 PM EST
To: "Redfield, Robert R. (CDC/OD)" (b) (6)
Cc: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: JID 2006, 193:1244-1249

Dear Bob,

Long time, no see. Our SARS study (JID 2006, 193:1244-1249; see the attachment) showed selective expansions of Vγ9Vδ2 T cells in survivors of SARS-CoV infection. Interestingly, stimulated Vγ9Vδ2 T cells also display an interferon-γ-dependent anti-SARS-CoV activity and are able to directly kill SARS-CoV-infected cells. Since it is very easy to activate human Vγ9Vδ2 T cells *in vivo* (e.g., using FDA-approved and relatively non-toxic drugs for treating bone-demineralization) and given the similarities between SARS-CoV and SARS-CoV-2, I thought that it could be potentially useful to bring these facts to your and Tony's attention, in spite of knowing that both of you are probably slightly busier these days than you would like to be.

All the best and good luck with everything,
Yours as ever,
Mirek

M. Malkovsky, MD, PhD, FRCPATH
Professor Emeritus, UW School of Medicine and Public Health
Mobile: (b) (6)
Office telephone and fax: (b) (6)
E-mail: (b) (6)